Building a comprehensively annotated and sequenced immune oncology NSCLC cohort

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038471

Enrollment

100

Registered

2026-03-16

Start date

2026-06-16

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34

Interventions

Group 1: Genomic and transcriptomic analyses are being conducted on patients with advanced non–small cell lung cancer (NSCLC) who are receiving immune checkpoint inhibitor (ICI) therapy, in order to i

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: advanced stage non-small cell lung cancer (NSCLC), patients get immunecheckpoint inhibitor therapy (ICI)

Exclusion criteria

Exclusion criteria: younger than 18 years, no ICI, not sufficient tissue for molecular analyses

Design outcomes

Primary

Measure	Time frame
a) Correlation of progression free survival (PFS) with the activity of metabolic pathways b) Correlation of PFS with the activity of cell death pathways	—

Secondary

Measure	Time frame
c) Correlatoin of PFS with histomorphological features d) Correlation of PFS with tumor mutational burden (TMB) e) Corrlation of PFS with mutations in tyrosine kinase receptor (RTK) and Ras/RAF pathway	—

Countries

Germany

Contacts

Public ContactAxel Hillmer

Universitätsklinik Köln

ahillmer@uni-koeln.de+49 221 478 85643

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026